NCT01290575 - Multiple Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions

Type 2 Diabetes

Interventions

DRUG

Placebo

capsule, Oral, 0.0mg, twice daily, 14 day

DRUG

Placebo

Capsule, Oral, 0.0mg, once daily, 14 day

DRUG

BMS-820132

Capsule, Oral, 15mg, twice daily, 14 day

DRUG

BMS-820132

Capsule, Oral, 60mg, twice daily, 14 day

DRUG

BMS-820132

Capsule, oral, 150mg, twice daily, 14 day

DRUG

BMS-820132

Capsule, Oral, 300mg, twice daily, 14 day

DRUG

BMS-820132

Capsule, Oral, 450mg, twice daily, 14 day

DRUG

BMS-820132

Capsule, Oral, To be determined (TBD), once daily, 14 day

DRUG

BMS-820132

Capsule, Oral, 5 mg, twice daily, 14 day

Trial Locations (5)

33014

Clinical Pharmacology Of Miami Inc., Miami

33143

Mra Clinical Research, Miami

72201

Osborne Research Center, Little Rock

78229

Cetero Research, San Antonio

85013

Dedicated Phase I, Inc., Phoenix